Skip to main content
SpringerLink
Log in

Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz

Diabetes mellitus, coronary artery disease and heart disease

  • leitlinien für die praxis
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Zusammenfassung

Die Zusammenhänge zwischen Diabetes mellitus, koronarer Herzkrankheit und Herzinsuffizienz sind wechselseitig. Bei Erstmanifestation einer koronaren Herzkrankheit sollte aktiv auf Diabetes mellitus gescreent werden, während bei an Diabetes mellitus erkrankten Patienten die kardiovaskuläre Risikostratifizierung immer in Zusammenschau sämtlicher Risikofaktoren, Biomarker und dem klinischen Befinden des Patienten durchgeführt werden sollte.

Summary

Diabetes mellitus, cardiovascular disease and heart failure are interacting dynamically. Patients being diagnosed with cardiovascular disease should be screened for diabetes mellitus. Enhanced cardiovascular risk stratification based on biomarkers, symptoms and classical risk factors should be performed in patients with pre-existing diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368:29–36.

    Article  PubMed  Google Scholar 

  2. Emerging Risk Factors C, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.

    Article  Google Scholar 

  3. Cubbon RM, Rajwani A, Abbas A, Gale CP, Grant PJ, Wheatcroft SB, et al. Hyperglycaemia, in relation to sex, and mortality after acute coronary syndrome. Eur J Cardiovasc Prev Rehabil. 2007;14:666–71.

    Article  PubMed  Google Scholar 

  4. Saely CH, Drexel H, Sourij H, Aczel S, Jahnel H, Zweiker R, et al. Key role of postchallenge hyperglycemia for the presence and extent of coronary atherosclerosis: an angiographic study. Atherosclerosis. 2008;199:317–22.

    Article  CAS  PubMed  Google Scholar 

  5. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668–73.

    Article  CAS  PubMed  Google Scholar 

  6. Marwick TH. Diabetic heart disease. Heart. 2006;92:296–300.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36:1718–27, 27a–27c.

    Article  PubMed  Google Scholar 

  8. Huelsmann M, Neuhold S, Strunk G, Moertl D, Berger R, Prager R, et al. Nt-probnp has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J. 2008;29:2259–64.

    Article  CAS  PubMed  Google Scholar 

  9. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the diad study. Diabetes Care. 2004;27:1954–61.

    Article  PubMed  Google Scholar 

  10. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28.

    Article  PubMed  Google Scholar 

  11. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.

    Article  CAS  PubMed  Google Scholar 

  12. Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

    Article  Google Scholar 

  13. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr., Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.

    Article  Google Scholar 

  14. Investigators OT, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28.

    Article  Google Scholar 

  15. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet. 2005;366:1279–89.

    Article  CAS  PubMed  Google Scholar 

  16. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410–8.

    Article  CAS  PubMed  Google Scholar 

  17. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010;53:2546–53.

    Article  CAS  PubMed  Google Scholar 

  18. Evans JM, Doney AS, AlZadjali MA, Ogston SA, Petrie JR, Morris AD, et al. Effect of metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol. 2010;106:1006–10.

    Article  CAS  PubMed  Google Scholar 

  19. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345–51.

    Article  CAS  PubMed  Google Scholar 

  20. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.

    Article  CAS  PubMed  Google Scholar 

  21. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(6):586.

    Article  Google Scholar 

  22. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Innere Medizin, Konventhospital der Barmherzigen Brüder Linz, Linz, Österreich

    Martin Clodi & Michael Resl

  2. Abteilung für Innere Medizin/VIVIT-Institut, Landeskrankenhaus Feldkirch, Feldkirch, Österreich

    Christoph Säly

  3. Abteilung für Innere Medizin, Krankenhaus der Barmherzigen Brüder Salzburg, Salzburg, Österreich

    Friedrich Hoppichler

  4. Klinik für Kardiologie und Internistische Intensivmedizin (Interne 1), Johannes Kepler Universität Linz, Med Campus III, Linz, Österreich

    Clemens Steinwender

  5. Abteilung für Innere Medizin II, Klinikum Wels-Grieskirchen, Wels, Österreich

    Bernd Eber

  6. ICMR – Institute for Cardiovascular and Metabolic Research, JKU Linz, Österreich

    Martin Clodi, Michael Resl, Clemens Steinwender & Bernd Eber

Authors
  1. Martin Clodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Säly
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Friedrich Hoppichler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Resl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Clemens Steinwender
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bernd Eber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Clodi.

Ethics declarations

Interessenkonflikt

M. Clodi hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, sanofi-aventis, Servier, Takeda.

C. Säly hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, sanofi-aventis, Pfizer, Takeda.

F. Hoppichler hat in Bezug auf diesen Artikel von folgenden Unternehmen, die teils auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: AstraZeneca, Boehringer Ingelheim, Janssen, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, sanofi-aventis, Servier, Takeda.

M. Resl hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Eli Lilly, Novo Nordisk, sanofi-aventis, Takeda.

C. Steinwender hat in Bezug auf diese Leitlinie keinen Interessenkonflikt.

B. Eber hat in Bezug auf diese Leitlinie keinen Interessenkonflikt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Clodi, M., Säly, C., Hoppichler, F. et al. Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz. Wien Klin Wochenschr 128 (Suppl 2), 212–215 (2016). https://doi.org/10.1007/s00508-016-0988-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-016-0988-7

Schlüsselwörter

Keywords

Search

Navigation